News Sentiment

RNTX sentiment intelligence

Rein Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.98 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-1.2% over one week, +2.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support Level - McClellan Summation

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction -1.2% Price digesting
Trend fit Trend inactive 2.3% over four weeks
Fair value -56.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
TradingKey 8
Market source 7
Stock Titan 4
GlobeNewswire 4
Investing.com 3
PR Newswire 3
DonanımHaber 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 16
Analyst action 5
Balance sheet 2
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
TradingView Direct company coverage

Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering

Rein Therapeutics has announced the closing of a $57.5 million underwritten public offering. The financial details of this offering were reported by Refinitiv. The article provides only this brief update without further elaboration.

Tone
Positive 66/100
Event
Market update
Published
18 May 2026 12:39
Source
TradingView
Investing.com Direct company coverage

Rein Therapeutics closes $57.5 million stock offering

Rein Therapeutics, Inc. (NASDAQ:RNTX) has successfully completed a $57.5 million public stock offering, selling 57.5 million shares at $1.00 each, including the underwriters' over-allotment option. The biopharmaceutical company plans to use the proceeds to fund its Phase 2 clinic

Tone
Positive 64/100
Event
Market update
Published
18 May 2026 12:39
Source
Investing.com
GlobeNewswire Direct company coverage

Rein Therapeutics Announces Closing of $57.5 Million

Rein Therapeutics announced the closing of a $57.5 million underwritten public offering, including the full exercise of the underwriters’ over-allotment option. The gross proceeds will be used to fund its Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis through c

Tone
Positive 70/100
Event
Market update
Published
18 May 2026 11:39
Source
GlobeNewswire